Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence

ABSTRACT Background: This study aimed to evaluate IgG and IgM levels in COVID-19 recurrence. Methods: The serum antibody levels and clinical data from 73 healthcare workers with SARS-CoV-2 divided into seroconverted (n=51) and non-seroconverted (n=22) groups were assessed. The presence of specific a...

Full description

Bibliographic Details
Published in:Revista da Sociedade Brasileira de Medicina Tropical
Main Authors: Maria da Penha Gomes Gouvea, Isac Ribeiro Moulaz, Thayná Martins Gouveia, Karen Evelin Monlevade Lança, Bárbara Sthefany de Paula Lacerda, Beatriz Paoli Thompson, Jéssica Polese, Marina Deorce de Lima, Rodrigo Ribeiro-Rodrigues, José Geraldo Mill, Valéria Valim
Format: Article in Journal/Newspaper
Language:English
Published: Sociedade Brasileira de Medicina Tropical (SBMT) 2022
Subjects:
COVID-19
SARS-CoV-2
Recurrence
Humoral Reactivity
Arctic medicine. Tropical medicine
RC955-962
Arctic
Online Access:https://doi.org/10.1590/0037-8682-0106-2022
https://doaj.org/article/dfcd4aa03830475bab3bfa00545fca26
Description
Summary:ABSTRACT Background: This study aimed to evaluate IgG and IgM levels in COVID-19 recurrence. Methods: The serum antibody levels and clinical data from 73 healthcare workers with SARS-CoV-2 divided into seroconverted (n=51) and non-seroconverted (n=22) groups were assessed. The presence of specific anti-nucleocapsid (anti-N) IgM and IgG for SARS-CoV-2 was evaluated. IgG antibodies to the SARS-CoV-2 spike receptor-binding domain were used to confirm non-seroconversion in all negative anti-N. Results: Four recurrent cases displayed mild symptoms and were non-seroconverted until the recurrence of symptoms. Conclusions: Undetectable anti-nucleocapsid IgM and IgG levels may be correlated with symptomatic COVID-19 recurrence.

Similar Items